Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/20616
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorBURZYKOWSKI, Tomasz-
dc.contributor.authorSaad, Everardo D.-
dc.date.accessioned2016-02-11T14:10:03Z-
dc.date.available2016-02-11T14:10:03Z-
dc.date.issued2016-
dc.identifier.citationCLINICAL CANCER RESEARCH, 22 (1), p. 268-268-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://hdl.handle.net/1942/20616-
dc.language.isoen-
dc.publisherAMER ASSOC CANCER RESEARCH-
dc.titleNeoadjuvant as Future for Drug Development in Breast Cancer-Letter-
dc.typeJournal Contribution-
dc.identifier.epage268-
dc.identifier.issue1-
dc.identifier.spage268-
dc.identifier.volume22-
local.format.pages1-
local.bibliographicCitation.jcatA1-
dc.description.notes[Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA. [Buyse, Marc; Burzykowski, Tomasz] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Hasselt, Belgium. [Burzykowski, Tomasz; Saad, Everardo D.] Int Inst Drug Dev, Louvain La Neuve, Belgium. [Saad, Everardo D.] Dendrix Res, Sao Paulo, Brazil.-
local.publisher.placePHILADELPHIA-
local.type.refereedRefereed-
local.type.specifiedLetter-
dc.identifier.doi10.1158/1078-0432.CCR-15-1047-
dc.identifier.isi000367550300030-
item.fullcitationBUYSE, Marc; BURZYKOWSKI, Tomasz & Saad, Everardo D. (2016) Neoadjuvant as Future for Drug Development in Breast Cancer-Letter. In: CLINICAL CANCER RESEARCH, 22 (1), p. 268-268.-
item.validationecoom 2017-
item.contributorBUYSE, Marc-
item.contributorBURZYKOWSKI, Tomasz-
item.contributorSaad, Everardo D.-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
crisitem.journal.issn1078-0432-
crisitem.journal.eissn1557-3265-
Appears in Collections:Research publications
Show simple item record

SCOPUSTM   
Citations

4
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

4
checked on May 8, 2024

Page view(s)

64
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.